MREO vs. CNTA, IDYA, MESO, AGIO, APGE, AMPH, IOVA, TARS, IBRX, and IRON
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Centessa Pharmaceuticals (CNTA), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Iovance Biotherapeutics (IOVA), Tarsus Pharmaceuticals (TARS), ImmunityBio (IBRX), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.
Mereo BioPharma Group vs.
Mereo BioPharma Group (NASDAQ:MREO) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.
Mereo BioPharma Group presently has a consensus price target of $7.83, indicating a potential upside of 162.42%. Centessa Pharmaceuticals has a consensus price target of $25.83, indicating a potential upside of 60.46%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, research analysts clearly believe Mereo BioPharma Group is more favorable than Centessa Pharmaceuticals.
62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 11.6% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Mereo BioPharma Group has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.
Mereo BioPharma Group has higher revenue and earnings than Centessa Pharmaceuticals.
Mereo BioPharma Group received 19 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 79.03% of users gave Mereo BioPharma Group an outperform vote while only 57.69% of users gave Centessa Pharmaceuticals an outperform vote.
Mereo BioPharma Group's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.
In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for Mereo BioPharma Group. Centessa Pharmaceuticals' average media sentiment score of 0.41 beat Mereo BioPharma Group's score of 0.35 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.
Summary
Mereo BioPharma Group beats Centessa Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
This page (NASDAQ:MREO) was last updated on 1/21/2025 by MarketBeat.com Staff
Free MREO Stock Alerts